Anticancer activity of complexes of the third row transition metals, rhenium, osmium, and iridium

CC Konkankit, SC Marker, KM Knopf, JJ Wilson - Dalton Transactions, 2018 - pubs.rsc.org
The clinical success of the platinum-based chemotherapeutic agents has prompted the
investigation of coordination and organometallic complexes of alternative metal centers for …

Construction of homo and heteronuclear Ru (II), Ir (III) and Re (I) complexes for target specific cancer therapy

S Pete, N Roy, B Kar, P Paira - Coordination Chemistry Reviews, 2022 - Elsevier
More than 10 million death tolls in 2020 were reported as a result of heinous impact of
cancer, making it second most prime cause of death after cardiovascular diseases. In …

Advances in novel iridium (III) based complexes for anticancer applications: A review

A Sharma, P Sudhindra, N Roy, P Paira - Inorganica Chimica Acta, 2020 - Elsevier
The need to synthesize an effective anticancer drug with minimal side effects has been the
aim and concern of the researchers around the world. Cytotoxicity and selectivity are the two …

Metallotherapeutic complexes with high selective properties for anti-neoplastic therapy

S De, S Kazi, S Banerjee, S Banerjee, N Sarkar… - Coordination Chemistry …, 2024 - Elsevier
It is one of the challenging works to deal with second major cause of death due to cancer
and to reduce the mortality rate caused by this. Researchers have been finding various …

Synthesis, crystal structure, DNA/bovine serum albumin binding and antitumor activity of two transition metal complexes with 4‐acylpyrazolone derivative

YP Zhang, Y Li, GC Xu, JY Li, HY Luo… - Applied …, 2019 - Wiley Online Library
Two new complexes, namely [Cu6L6](1) and [Zn (HL) 2](2)(H2L= N‐(1‐phenyl‐3‐methyl‐4‐
propenylidene‐5‐pyrazolone)‐2‐furancarboxylic acid hydrazide), have been synthesized …

Research Progress of Metal Anticancer Drugs

Y Bai, G Aodeng, L Ga, W Hai, J Ai - Pharmaceutics, 2023 - mdpi.com
Cancer treatments, including traditional chemotherapy, have failed to cure human
malignancies. The main reasons for the failure of these treatments are the inevitable drug …

Electronic effects on reactivity and anticancer activity by half-sandwich N, N-chelated iridium (III) complexes

L Guo, H Zhang, M Tian, Z Tian, Y Xu, Y Yang… - New Journal of …, 2018 - pubs.rsc.org
The synthesis and characterization of a series of organometallic half-sandwich N, N-
chelated iridium (III) complexes bearing a range of electron-donating and withdrawing …

Synthesis and biological evaluation of mixed-ligand cyclometalated iridium (III)–quinoline complexes

Y Yang, CM Wang, FH Pan, QP Qin, QJ Xie… - Dalton …, 2021 - pubs.rsc.org
With the aim of gaining new insight into the underlying apoptosis mechanisms and in vivo
efficacy of cyclometalated Ir (III) complexes as metalodrugs, six new cyclometalated Ir (III) …

Ruthenium and iridium based mononuclear and multinuclear complexes: A Breakthrough of Next-Generation anticancer metallopharmaceuticals

B Kar, N Roy, S Pete, P Moharana, P Paira - Inorganica Chimica Acta, 2020 - Elsevier
A great threat to human life due to fatal impact of cancer stirred up the researchers to be
immersed in deep research on metallopharmaceuticals which made immediate available of …

Cytotoxic and apoptotic effects of ternary silver (i) complexes bearing 2-formylpyridine thiosemicarbazones and 1, 10-phenanthroline

DES Silva, AB Becceneri, MC Solcia… - Dalton …, 2020 - pubs.rsc.org
New silver (I) compounds containing 2-formylpyridine-N (4)-R-thiosemicarbazones and 1,
10-phenanthroline (phen) were synthesized and characterized by spectroscopic techniques …